WeConnectPatients.com · Blood & Cancer Care

Your bone marrow isn’t making blood the way it should. And there are more options now than simply monitoring and waiting.

MDS is a group of blood disorders where your bone marrow doesn’t produce enough healthy blood cells. It’s complex. But understanding it gives you power over what comes next.

U.S. Diagnoses/Year

New cases of MDS diagnosed annually in America

Median Age

Most people are diagnosed in their early 70s

AML Progression Risk

Applies only to higher-risk MDS patients; risk is much lower for lower-risk disease. Individual outlook depends on your IPSS-R score and molecular profile.

Quality-of-Life Issue

Fatigue is the most reported symptom affecting daily life

Your bone marrow has one job. And it’s struggling.

Myelodysplastic syndromes — MDS — happen when your bone marrow starts making blood cells that don’t work properly. MDS is not one condition — it is a group of related conditions classified by international medical organizations (including the World Health Organization) based on the type and degree of abnormality in the bone marrow. They range from slow-moving to serious. Knowing where you fall changes everything.

Your bone marrow is supposed to produce red blood cells, white blood cells, and platelets. With MDS, it produces cells that are abnormal or immature. They don’t function the way they should — and often don’t survive long enough to do their job.

The result? You feel exhausted. Your immune system can’t fight infections as well. You may bruise easily or bleed more than expected. These aren’t minor inconveniences. They’re signs that your blood isn’t keeping up.

About 20,000 people are diagnosed with MDS in the U.S. each year. The median age at diagnosis is 72, and it is slightly more common in men — but MDS affects people of all ages, genders, and backgrounds. Younger adults, women, and people from all communities receive this diagnosis. Access to specialized hematology care varies widely, and seeking out a center with MDS expertise can make a meaningful difference in your care.

What makes MDS especially confusing is that it’s not a single path. Some people live with it for years with minimal treatment. Others face a higher risk of progressing to acute myeloid leukemia (AML) and need more aggressive care. That’s why your specific risk profile — not a general statistic — should drive every conversation you have with your doctor.

What drives MDS

MDS starts in your bone marrow. Understanding what drives it helps you make sense of what’s happening.

Your bone marrow

Your bone marrow is the factory that makes your blood cells. In MDS, the stem cells in that factory develop genetic changes that cause them to produce defective cells. These abnormal cells crowd out the healthy ones.

Genetic mutations

Specific gene changes — like TP53, SF3B1, or ASXL1 — drive different forms of MDS. Some mutations predict a slower course. Others signal a more aggressive condition. Molecular testing helps your doctor understand which kind you’re dealing with.

Prior treatments

Previous chemotherapy or radiation therapy for another cancer can damage bone marrow and lead to MDS years later. This is called therapy-related MDS, and it accounts for a meaningful number of cases.

Environmental exposures

Long-term exposure to certain chemicals — like benzene — or heavy metals has been linked to MDS. Military veterans, industrial workers, and smokers have higher-than-average rates.

Age and biology

As you age, your bone marrow accumulates more genetic changes. That’s a big reason MDS is more common after 60. Being male also increases risk slightly, though researchers are still working out why.

Not your fault

MDS isn’t caused by something you did or didn’t do. Most cases have no clear preventable cause. This is a condition of biology, not behavior.

How MDS is diagnosed

Diagnosing MDS takes more than a blood test. It requires a clear picture of what’s happening inside your bone marrow.

Blood work (CBC)

A complete blood count often reveals the first clues: low red blood cells, low white blood cells, or low platelets — sometimes all three. These counts tell your doctor something isn’t right, but not yet what.

Bone marrow biopsy

This is the definitive test. A small sample of marrow from your hip bone is examined under a microscope to look for abnormal cells, the percentage of immature cells (called blasts — cells that haven’t fully developed), and signs of dysplasia — meaning cells that look structurally abnormal under a microscope. It’s uncomfortable but essential.

Cytogenetic testing

Your marrow sample is tested for chromosome abnormalities. Certain changes — like deletion of chromosome 5q — point to specific subtypes of MDS with different treatment paths and outlooks.

Molecular profiling

Newer genetic tests look for specific mutations in your bone marrow cells. These results help your doctor assign a risk score, predict how the condition may behave, and choose the most targeted treatment approach.

Risk stratification (IPSS-R)

All of this information feeds into a risk scoring system called the IPSS-R — the Revised International Prognostic Scoring System for Myelodysplastic Syndromes. It categorizes you as very low, low, intermediate, high, or very high risk. That score drives every treatment decision — and it should be explained to you clearly.

Treatment depends on your risk level

MDS treatment is risk-stratified. What’s right for you depends on your specific type, your risk score, and how the condition is affecting your daily life.

Lower-Risk

Supportive Care & Growth Factors

For lower-risk MDS, the focus is often on managing symptoms. Medicines called erythropoiesis-stimulating agents (ESAs) signal your body to make more red blood cells. Newer agents can reduce or eliminate the need for transfusions in many patients. The goal: keep your counts stable and your quality of life intact.

Lower-Risk

Targeted Therapies

If you have specific genetic features — like del(5q) — certain targeted medicines can be highly effective. Newer agents are expanding what’s possible for people who don’t respond to initial treatments — including recently approved medications and others being studied in clinical trials. Molecular testing helps match you to the right therapy.

Higher-Risk

Hypomethylating Agents

For higher-risk MDS, drugs like azacitidine and decitabine — a class called hypomethylating agents — work by reactivating genes that help control cell growth. These are typically given in cycles and can improve blood counts, reduce transfusion needs, and slow progression toward leukemia.

Curative Option

Stem Cell Transplant

A stem cell transplant is the only potentially curative treatment for MDS. It’s intensive and carries real risks, and eligibility involves more than medical factors — your overall fitness, access to a transplant center, and support system at home all play a role. For eligible patients with higher-risk disease, it offers a potential path toward long-term remission. Financial assistance programs and patient navigators exist to help — ask your care team.

All treatments carry potential side effects and require careful monitoring. Talk to your hematologist about which risks and benefits apply to your specific situation.

“The hardest part wasn’t the diagnosis. It was not knowing what to do next. Once we had a plan, everything changed.”

Reflects common patient experiences

Cost is a real barrier for many MDS patients. Treatment costs vary widely depending on insurance, medication type, and frequency of monitoring. Ask your care team about manufacturer patient assistance programs, hospital financial counselors, and organizations like the Leukemia & Lymphoma Society’s financial assistance programs. Geographic access to hematologists and infusion centers also varies — telehealth consultations are increasingly available for follow-up appointments.

Answers to common questions

Living with MDS raises real, practical questions. Here are honest answers to some of the most common ones.

Is MDS cancer?

It depends on who you ask. MDS is officially classified as a blood cancer by the World Health Organization. But many people with lower-risk MDS live for years with careful monitoring and targeted support. What matters isn’t the label — it’s understanding your specific risk and having a plan.

Will MDS turn into leukemia?

It can. About 25–35% of people with higher-risk MDS may progress to acute myeloid leukemia (population-level estimate; individual outcomes vary). For lower-risk patients, that number is much lower — around 5–10% over five years. Your IPSS-R risk score and molecular profile are the best predictors. Ask your doctor where you stand.

Why am I so tired all the time?

Fatigue is the number one quality-of-life complaint in MDS, and it’s not just being “a little tired.” Low red blood cells mean less oxygen reaching your muscles and brain. This can also affect your ability to concentrate, remember things, or think clearly — and fatigue in MDS can be worse than your hemoglobin level would predict. Tell your doctor how it actually affects your day, including any cognitive symptoms.

What are transfusions, and will I need them?

If your red blood cell count drops too low, you may need regular blood transfusions — sometimes every few weeks. Transfusions help you feel better temporarily, but they’re a logistical commitment. Newer treatments aim to reduce or eliminate transfusion dependence. Ask your doctor if those options apply to you.

Should I get a second opinion?

Yes. MDS is complex enough that it’s worth being seen by a hematologist-oncologist who specializes in it. Academic medical centers and MDS-specific programs can offer access to the latest treatments and trials. You’re not being difficult. You’re being smart.

How do I explain MDS to my family?

Keep it simple: “My bone marrow isn’t making healthy blood cells the way it should. There are treatments that can help.” Most people don’t need the medical deep dive — they need to know what you need and how they can help. If a family member, partner, or caregiver wants to be more involved in your care, bring them to appointments and direct them to resources from the MDS Foundation — there are guides specifically for people supporting someone with MDS.

What about depression and anxiety?

Both are common in MDS — more common than most doctors screen for. Fatigue, uncertainty about the future, and the grind of regular appointments all take a toll. If you’re struggling, say so. Depression is treatable, and addressing it makes everything else more manageable.

Are there communities I can connect with?

The MDS Foundation offers support groups and educational resources specifically for people with MDS. The Leukemia & Lymphoma Society is another strong resource. Online communities can help too, but look for moderated, disease-specific groups. Connecting with people who get it makes a real difference.

Research & Progress

The science is advancing

MDS research has advanced significantly in recent years. Scientists now understand the specific genetic mutations that drive different forms of MDS, and that knowledge is translating into treatments that target the condition at its source. This isn’t a field standing still.

What’s in the pipeline: As of early 2026, combination therapies that pair established drugs with newer targeted agents are being actively studied. Next-generation treatments are being tested for both lower-risk and higher-risk MDS. And biomarker-driven approaches that match patients to therapies based on their individual molecular profile — not just their diagnosis — are reshaping how care is delivered.

Clinical trials are where these advances happen first. Participating gives you access to emerging treatments, specialized monitoring, and a care team focused specifically on MDS. Your standard care continues regardless. No obligation. If you’re concerned about eligibility because of your age, other health conditions, or where you live, ask your care team directly — many trials are designed with older adults in mind, and eligibility criteria vary by study.

You deserve a plan that fits your MDS. Not just the standard playbook.

Whether you were just diagnosed or you’ve been managing MDS for years, clinical research may open doors worth exploring.

Not sure where to start?

Walking into a hematology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: NCCN, MDS Foundation, Leukemia & Lymphoma Society, American Cancer Society, Mayo Clinic, peer-reviewed literature (2009–2025), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.